Tikva

Tikva Therapeutics is a pre-clinical stage biotechnology company focused on developing next-generation, off-the-shelf cell therapies for autoimmune diseases and oncology. The company leverages advanced genome engineering to create stealth immune cells designed to evade host immune detection, potentially overcoming the limitations of current autologous and allogeneic therapies. By utilizing a proprietary platform, Tikva aims to provide scalable and more accessible treatments for patients with high unmet medical needs. Their approach integrates synthetic biology and immunology to engineer T cells with enhanced persistence and safety profiles. The company is currently prioritizing applications in autoimmune conditions such as systemic lupus erythematosus, where cell therapy has shown transformative potential.